A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2023 Results assessing case photography documenting outcomes in the PSOARING trials (NCT03956355, NCT03983980 and NCT04053387) published in the Dermatology and Therapy
10 May 2023 Results assessing the long-term, health-related quality of life and patient satisfaction (Patient-reported outcomes) with tapinarof for the treatment of plaque psoriasis, published in the Journal of the American Academy of Dermatology.
12 Jan 2023 According to a Dermavant Sciences media release, data will be presented at the 20th Annual Winter Clinical Dermatology Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com